Inventor · disambiguated record
Todd Webster Shearer
Also filed as: SHEARER TODD · SHEARER TODD WEBSTER
23 granted patents·17 pending applications·96 citations·filing 2021–2025
95Inventor score
Top patents by PatentIndex Score
40 records- 0197US12011424B2Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Jun 18, 2024·4 cites·6 claims
- 0297US11819487B2Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Nov 21, 2023·9 cites·21 claims
- 0397US11806322B2Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Nov 7, 2023·6 cites·26 claims
- 0497US11806321B2Non-linear dosing of mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Nov 7, 2023·11 cites·24 claims
- 0596US11957662B2Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Apr 16, 2024·8 cites·17 claims
- 0696US11951096B2Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Apr 9, 2024·8 cites·25 claims
- 0796US11938116B2Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Mar 26, 2024·8 cites·17 claims
- 0896US11925620B1Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Mar 12, 2024·8 cites·19 claims
- 0996US11925619B2Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Mar 12, 2024·8 cites·16 claims
- 1096US11872211B2Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Jan 16, 2024·12 cites·22 claims
- 1196US11839595B2Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Dec 12, 2023·3 cites·26 claims
- 1295US11883375B2Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Jan 30, 2024·2 cites·30 claims
- 1394US12324791B2Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Jun 10, 2025·1 cites·2 claims
- 1494US12138246B2Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2024·Granted Nov 12, 2024·2 cites·28 claims
- 1594US12036207B2Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Jul 16, 2024·2 cites·18 claims
- 1694US12011435B2Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2024·Granted Jun 18, 2024·2 cites·30 claims
- 1794US12011434B2Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Jun 18, 2024·2 cites·17 claims
- 1890US12295925B2Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2024·Granted May 13, 2025·0 cites·25 claims
- 1990US12257215B2Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2024·Granted Mar 25, 2025·0 cites·22 claims
- 2090US12220390B2Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2024·Granted Feb 11, 2025·0 cites·30 claims
- 2189US2024216305A1Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2289US2024216306A1Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2389US2024226037A1Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2488US12263146B2Non-linear dosing of mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Apr 1, 2025·0 cites·15 claims
- 2583US2025275932A1Treatment of neurofibromatosis type 1 (nf1) associated plexiform neurofibromas (pn) in pediatric patients with mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2681US2025268850A1Non-linear dosing of mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2780US12186305B2Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2024·Granted Jan 7, 2025·0 cites·16 claims
- 2876US2025025446A1Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2971US2023241028A1Treatment of ovarian cancer with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3069US12390430B1Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2024·Granted Aug 19, 2025·0 cites·18 claims
- 3169US2023087828A1Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereofSPRINGWORKS THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3267US2023049311A1Methods of treating desmoid tumors with (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamideSPRINGWORKS THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3366US2024180874A1Improved treatment of ovarian cancer with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3465US2024316007A1Compositions and treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3563US2024122881A1Combination for use in treating cancersSPRINGWORKS THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3660US2023293464A1Treatment of pancreatic ductal adenocarcinoma with mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3755US2023121547A1A combination therapy with nirogacestat and a bcma-directed therapy and uses thereofSPRINGWORKS THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3854US2024343819A1Methods of treating multiple myelomaSEAGEN INC·Filed 2022·Application pending·0 cites
- 3952US2023128315A1Co-administration of mirdametinib and lifirafenib for use in treating cancersBEIGENE LTD·Filed 2021·Application pending·0 cites
- 4047US2023112444A1Combination therapies of chimeric antigen receptors targeting b-cell maturation antigen and gamma secretase inhibitorsALLOGENE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Todd Webster Shearer files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →